About MicuRx Pharmaceuticals
MicuRx Pharmaceuticals is a company based in Foster City (United States) founded in 2007 by Zhengyu Yuan and Mikhail F Gordeev.. MicuRx Pharmaceuticals has raised $389.28 million across 10 funding rounds from investors including Korea Investment Holdings, CARB-X and Legend Capital. The company has 4 employees as of December 31, 2022. MicuRx Pharmaceuticals operates in a competitive market with competitors including Kriya Therapeutics, Paratek Pharma, Spero Therapeutics, DermBiont and Cempra, among others.
- Headquarter Foster City, United States
- Employees 4 as on 31 Dec, 2022
- Founders Zhengyu Yuan, Mikhail F Gordeev
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Micurx Pharmaceuticals
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$389.28 M (USD)
in 10 rounds
-
Latest Funding Round
$106.93 M (USD), Series E
Dec 23, 2020
-
Investors
Korea Investment Holdings
& 9 more
-
Employee Count
4
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of MicuRx Pharmaceuticals
MicuRx Pharmaceuticals has successfully raised a total of $389.28M across 10 strategic funding rounds. The most recent funding activity was a Series E round of $106.93 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Series E — $106.9M
-
First Round
First Round
(25 Jun 2007)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2020 | Amount | Series E - MicuRx Pharmaceuticals | Valuation | Legend Capital | |
| Dec, 2020 | Amount | Series E - MicuRx Pharmaceuticals | Valuation |
investors |
|
| Aug, 2020 | Amount | Series D - MicuRx Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MicuRx Pharmaceuticals
MicuRx Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Korea Investment Holdings, CARB-X and Legend Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture Capital firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Investment holding firm established in Seoul in 2003.
|
Founded Year | Domain | Location | |
|
AI solutions are provided for industrial monitoring and efficiency.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MicuRx Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - MicuRx Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Micurx Pharmaceuticals Comparisons
Competitors of MicuRx Pharmaceuticals
MicuRx Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Paratek Pharma, Spero Therapeutics, DermBiont and Cempra, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Microbial therapeutics for skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| domain | founded_year | HQ Location |
Drugs for antibiotic-resistant infections and cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Micurx Pharmaceuticals
Frequently Asked Questions about MicuRx Pharmaceuticals
When was MicuRx Pharmaceuticals founded?
MicuRx Pharmaceuticals was founded in 2007.
Where is MicuRx Pharmaceuticals located?
MicuRx Pharmaceuticals is headquartered in Foster City, United States. It is registered at Foster City, California, United States.
Who is the current CEO of MicuRx Pharmaceuticals?
Zhengyu Yuan is the current CEO of MicuRx Pharmaceuticals. They have also founded this company.
Is MicuRx Pharmaceuticals a funded company?
MicuRx Pharmaceuticals is a funded company, having raised a total of $389.28M across 10 funding rounds to date. The company's 1st funding round was a Series D of $42.98M, raised on Jun 25, 2007.
How many employees does MicuRx Pharmaceuticals have?
As of Dec 31, 2022, the latest employee count at MicuRx Pharmaceuticals is 4.
What does MicuRx Pharmaceuticals do?
MicuRx Pharmaceuticals develops antibiotics against multidrug-resistant (MDR) superbug infections. It is involved in the development of a portfolio that comprises a pipeline of antimicrobial agents to treat gram-positive bacteria, gram-negative bacteria, and fungal infections. Products include MRX-I, an oxazolidinone antibiotic for treating methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococci infections which is in phase 3 of the clinical trial; and MRX-II, an oxazolidinone antibiotic for treating hospital-acquired infections. Other candidates are MRX-4 and MRX-8 which are effective against gram-positive and gram-negative bacteria are in phase 2 and 1 of the clinical trial.
Who are the top competitors of MicuRx Pharmaceuticals?
MicuRx Pharmaceuticals's top competitors include Spero Therapeutics, Vedanta Biosciences and Paratek Pharma.
Who are MicuRx Pharmaceuticals's investors?
MicuRx Pharmaceuticals has 10 investors. Key investors include Korea Investment Holdings, CARB-X, Legend Capital, Yingke Capital, and AI PRO.